Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

Antiviral Research

Volumn 35, Issue 1, 1997, Pages 53-63

  Borin, Marie T ^a   Chambers, James H ^a   Carel, Barbara J ^a   Freimuth, William W ^a   Aksentijevich, Sophia ^b   Piergies, Antoni A ^b  

^a PFIZER INC   (United States)

^b EVANSTON HOSPITAL   (United States)

Author keywords

Delavirdine; Drug drug interaction; Human immunodeficiency virus; Pharmacokinetics; Rifabutin

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; CYTOCHROME P450 ISOENZYME; DELAVIRDINE; DRUG METABOLITE; ENZYME INDUCING AGENT; RIFABUTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG OXIDATION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; INDOLES; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RIFABUTIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030926418     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00011-9     Document Type: Article

References (25)

1. 3, who are maintained on a stable dose of AZT (abstract). In: Program and Abstracts of the First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology, Washington, D.C.
2. Borin, M.T., Chambers, J.H., Carel, B.J., Gagnon, S. and Freimuth, W.W. (1997) Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther., in press.
3. Brogden, R.N. and Fitton, A. (1994) Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 983-1009.
4. Cheng, C-L., Smith, D.E., Carver, P.L., Cox, S.R., Watkins, P.B., Blake, D.S., Kauffman, C.A., Meyer, K.M., Amidon, G.L. and Stetson, P.L. (1997) Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin. Pharmacol. Ther., in press.
5. Chong, K.T., Pagano, P.J. and Hinshaw, R.R. (1994) Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits HIV-1 replication in vitro. Antimicrob. Agents Chemother. 38, 288-293.
6. Cox, S.R., Ferry, J.J., Batts, D.H., Carlson, G.F., Schneck, D.W., Herman, B.D., Delia-Coletta, A.A., Chambers, J.H., Carel, B.J., Stewart, F., Buss, N. and Brown, A. (1997) Delavirdine and marketed protease inhibitors: Pharmacokinetic interaction studies in healthy volunteers (abstract). In: Program and Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. American Society for Microbiology, Washington, D.C.
7. Della Bruna, C., Schioppacassi, C., Ungheri, D., Jabes, D., Morvillo, E. and Sanfilippo, A. (1983) LM 427, a new spiropiperidyl rifamycin: In vitro and in vivo studies. J. Antibiot. (Tokyo) 36, 1502-1506.
8. Dueweke, T.J., Poppe, S.M., Romero, D.L., Swaney, S.M., So, A.G., Downey, K.M., Althaus, I.W., Reusser, F., Busso, M., Resnick, L., Mayers, D.I. and Lane, J. (1993) U-90152S, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127-1131.
9. Freimuth, W.W., Wathen, L.K., Cox, S.R., Chuang-Stein, C.J., Greenwald, C.A., Daenzer, C.L., Wang, Y. and Delavirdine Team. (1996) Delavirdine (DLV) in combination with zidovudine (ZDV) causes sustained antiviral and immunological effects in HIV-1 infected individuals (abstract). In: Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections. American Society for Microbiology, Washington, D.C.
10. Freimuth, W.W., Chuang-Stein, C.J., Greenwald C.A., Cox, S.R., Edge-Padbury, B.A., Carberry, P.A., Wathen, L.K. and Delavirdine Team. (1996) Delavirdine (DLV) plus didanosine (ddI) combination therapy has sustained surrogate marker response in advanced HIV-1 population (abstract). In: Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections. American Society for Microbiology, Washington, D.C.
11. Ged, C., Rouillon, J.M., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P. and Maurel, P. (1989) The increase in urinary excretion of 6-β- hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Brit. J. Clin. Pharmacol. 28, 373-387.
12. Gillum, J.G., Israel, D.S. and Polk, R.E. (1993) Pharmacokinetic drug interactions with antimicrobial agents. Clin. Pharmacokinet. 25, 450-482.
13. Hafner, R., Bethel, J., Power, M., Landry, B., Banach M., Mole, L., Standiford H., Follansbee, S., Kumar, P., Raasch, R., Cohn, D., Mushatt, D., Drusano, G. and the DATRI 001 Study Group. (1997) Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in HIV-positive volunteers. Ann. Intern. Med., in press.
14. Heifets, L.B., Iseman, M.D. and Lindholm-Levy, P.J. (1986) Bacteriostatic and bactericidal effects of rifabutin (ansamycin LM 427) on Mycobacterium avium clinical isolates. In: M. Casal (Ed), Mycobacteria of Clinical Interest, pp. 180-183, Elsevier Science, Amsterdam.
15. Heifets, L.B., Iseman, M.D. and Lindholm-Levy, P.J. (1987) Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp. Clin. Res. 13, 529-538.
16. Lau, Y.Y., Hanson, G.D. and Carel, B.J. (1996) Determination of rifabutin by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. Biomed. Appl. 676, 125-130.
17. Perucca, E., Grimaldi, R., Frigo, G.M., Sardi, A., Monig, H. and Ohnhaus, E.E. (1988) Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol. 34, 595-599.
18. Romero, D.L., Busso, M., Tan, C-K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff, P.A., Downey, K.M., So, A.G., Resnick, L. and Tarpley, W.G. (1991) Novel non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 8, 8806-8810.
19. Skinner, M.H., Hsieh, M., Torseth, J., Pauloin, D., Bhatia, G., Harkonen, S., Merigan, T.C. and Blaschke, T.F. (1989) Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33, 1237-1241.
20. Staton, B.A., Johnson, M.G., Friis, J.M. and Adams, W.J. (1995) Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-despropyl metabolite in human plasma. J. Chromatogr. B. Biomed. Appl. 668, 99-106.
21. Strolin-Benedetti, M., Efthymiopoulos, C., Sassella, D., Moro, E. and Repetto, M. (1990) Autoinduction of rifabutin metabolism in man. Xenobiotica 20, 1113-1119.
22. Trapnell, C.B., Lavelle, J.P., O'Leary, C.R., James, D.S., Li, R., Colburn, D.R., Woosley, L. and Narang, P.K. (1993) Rifabutin does not alter fluconazole pharmacokinetics (abstract). Clin. Pharmacol. Ther. 53, 196.
23. Voorman, R.L., Maio, S.M. and Wang, X. (1995) Mechanismbased inactivation of rat and human cytochrome P450 3A by delavirdine (abstract). Ninth International Conference on Cytochrome P450, Zurich, Switzerland.
24. Wallace, R.J., Brown, B.A., Griffith, D.E., Girard, W. and Tanaka, K. (1995) Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 171, 747-750.
25. Yamaoka, K., Nakagawa, T. and Uno, T. (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6, 165-175.